Free Trial

Arcus Biosciences, Inc. (NYSE:RCUS) Short Interest Update

Arcus Biosciences logo with Medical background

Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) saw a significant increase in short interest in the month of May. As of May 15th, there was short interest totalling 9,900,000 shares, an increase of 25.2% from the April 30th total of 7,910,000 shares. Based on an average daily trading volume, of 1,170,000 shares, the days-to-cover ratio is presently 8.5 days. Approximately 15.5% of the company's shares are short sold.

Arcus Biosciences Stock Performance

Shares of NYSE:RCUS traded up $0.01 during trading on Thursday, hitting $9.61. The company's stock had a trading volume of 313,853 shares, compared to its average volume of 1,080,564. The company has a 50-day moving average of $8.33 and a 200-day moving average of $11.51. Arcus Biosciences has a 12 month low of $6.50 and a 12 month high of $18.98. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. The firm has a market cap of $1.02 billion, a price-to-earnings ratio of -3.05 and a beta of 0.88.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($1.14) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.12). Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The business had revenue of $28.00 million during the quarter, compared to analysts' expectations of $38.61 million. During the same period in the previous year, the business earned ($0.05) earnings per share. The business's quarterly revenue was down 80.7% on a year-over-year basis. On average, sell-side analysts expect that Arcus Biosciences will post -3.15 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of RCUS. R Squared Ltd acquired a new position in Arcus Biosciences during the 4th quarter valued at approximately $26,000. Strs Ohio acquired a new stake in Arcus Biosciences during the first quarter worth about $67,000. E Fund Management Co. Ltd. acquired a new stake in Arcus Biosciences during the first quarter worth about $82,000. Lazard Asset Management LLC increased its position in Arcus Biosciences by 3,321.3% during the fourth quarter. Lazard Asset Management LLC now owns 6,261 shares of the company's stock worth $93,000 after purchasing an additional 6,078 shares during the last quarter. Finally, Knott David M Jr purchased a new position in Arcus Biosciences during the first quarter worth about $94,000. Institutional investors own 92.89% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Morgan Stanley decreased their price objective on shares of Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. The Goldman Sachs Group cut their target price on shares of Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. HC Wainwright raised shares of Arcus Biosciences from a "neutral" rating to a "buy" rating and increased their target price for the stock from $18.00 to $24.00 in a research note on Wednesday, February 26th. Wedbush reissued an "outperform" rating and set a $33.00 target price on shares of Arcus Biosciences in a research note on Wednesday, May 7th. Finally, Wells Fargo & Company dropped their price objective on shares of Arcus Biosciences from $29.00 to $26.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $24.13.

Check Out Our Latest Stock Report on RCUS

About Arcus Biosciences

(Get Free Report)

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.

Further Reading

Should You Invest $1,000 in Arcus Biosciences Right Now?

Before you consider Arcus Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.

While Arcus Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Dirt-Cheap Stocks in a Market That’s Getting Expensive
Top 3 Defense Stocks to Profit From $175 Billion Golden Dome
Top 5 Stocks for June: AI Picks That Aren’t NVIDIA

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines